SuperNova Diagnostics(R) to Present at Biotech Showcase(TM) 2011 During J.P. Morgan Healthcare Conference January 10-13By Supernova Diagnostics Inc., PRNE
Tuesday, January 4, 2011
WASHINGTON, LONDON and HONG KONG, January 5, 2011 - SuperNova Diagnostics(R), Inc., a privately-held global diagnostics
company for human and non-human health applications, announced today that
Neil J. Campbell, president and CEO, will present at Biotech Showcase 2011 in
conjunction with the J.P. Morgan Healthcare Conference in San Francisco, CA.
Mr. Campbell's presentation will be given at the Parc 55 Wyndham Hotel on
Wednesday, January 12, 2011 at 3:30 p.m. PST. "We are delighted to be
presenting at a renowned conference such as Biotech Showcase," said Mr.
Campbell. "Biotech Showcase and the J.P. Morgan Healthcare Conference provide
a unique opportunity to present to a diverse group of first-class investors
and executives interested in medical and industrial diagnostics."
AmpCrystal(R), SuperNova Diagnostics' lead technology and its multiple
product formats, allows for minimally trained individuals (advanced
CLIA-waived) to test for a wide range of protein analytes and can detect
directly un-amplified DNA in humans, animals or environmental samples.
Time-to-result has been shown in prototypes to be reduced to minutes on
the spot versus the hours or days required when sending samples to a central
laboratory or processing in regional satellite laboratories. With three
integrated capabilities (sample collector/processor, analytical disposable,
and the readout device), the technology is simpler, more robust, faster and
significantly less expensive than existing POC systems.
Significant advantages of AmpCrystals are direct detection of samples,
simplification of product designs, ability to lower costs of delivery and
broaden range of assay formats from the central laboratory.
About SuperNova Diagnostics(R), Inc.
SuperNova(R) is a development-stage diagnostics company with a
proprietary platform for conducting diagnostics at the site of interest with
point-of-care in human health and point-of-use for non-human health
applications. A powerful proprietary nanochemistry, AmpCrystal(R), can
delivery novel, next generation performance for pathogens, proteins, and
directly measure DNA without PCR with ultra-low sensitivity and specificity
while not sacrificing a dynamic range of measurements. SuperNova can be
utilized in a wide range of diagnostic formats (lateral flow, self-contained
cartridges, microtitre, microarrays, closed systems, research products and
OEM). SuperNova(R) - Putting the Laboratory in the Palm of Your Hand(R).
For additional information, please visit
Media Contacts: Tiberend Strategic Advisors, Inc. +1-212-827-0020 Tamara Bright, email@example.com or Farrell Denby, firstname.lastname@example.org
Tamara Bright, tbright at tiberend.com, or Farrell Denby, fdenby at tiberend.com, both of Tiberend Strategic Advisors, Inc.: +1-212-827-0020
Tags: Asia, california, District of Columbia, England, Hong Kong, January 5, London And Hong Kong, Supernova Diagnostics Inc., Washington